The administration of certain monoclonal anti-Sm antibodies (2G7, 7.13) induced most MRL/lpr mice to become anti-Sm positive by 5 mo of age, although other anti-Sm monoclonals (Y2, Y12) suppressed the spontaneous response. Positive anti-Sm antibody enhancement occurred efficiently only in MRL/lpr mice and not in other systemic lupus erythematosus mice that have little spontaneous anti-Sm production. The enhancement by anti-Sm antibodies was specific for the anti-Sm response. The mechanism of the passive antibody enhancement was apparently not isotype-or idiotype-related. The fine specificity of the anti-Sm monoclonal antibody may be essential to its enhancing or suppressing effects, since both enhancing monoclonals recognized only the D Sm polypeptide, whereas both suppressing monoclonals saw the D and the B polypeptides. Furthermore, analysis of serial bleeds from unmanipulated MRL mice that developed anti-Sm positivity showed that the D specificity almost always appeared first. We hypothesize, therefore, that those animals in which an anti-Sm response is initiated by D-specific B-cell clones can become serologically positive with the aid of a positive feedback loop. In contrast, animals in which the initial specificity is for both B and D peptides would be prevented from developing a full anti-Sm response. (J. Clin. Invest. 1990. 85:86-92.) mixed leukocyte reaction * monoclonal anti-Sm antibody -passive antibody-systemic lupus erythematosus mice
Introduction
Anti-Sm antibodies are specific markers ofsystemic lupus erythematosus (SLE)' in humans and in murine models of this disease (1, 2) . These autoantibodies are directed at one or more peptides of nuclear RNA-protein complexes, termed small nuclear ribonucleoproteins (snRNPs [3] ), and are predominantly of the IgG isotypes (4, 5) . Only a minority of humans with SLE develop this specificity; remarkably, this is also the case for genetically identical SLE-prone mice. We have previously investigated in detail the expression of anti-Sm antibodies in the inbred MRL mouse strains in order to elucidate this unusual pattern of autoantibody production (6) . We found that 5-mo-old MRL/Mp-lpr/lpr (MRL/lpr) mice have a 25% prevalence of anti-Sm positivity, as determined by immunodiffusion. Quantitative analysis with a much more sensitive ELISA assay indicated that immunodiffusion-positive sera had high titers of anti-Sm antibodies, whereas immunodiffusion-negative sera were indistinguishable from sera obtained from normal mice. The distribution of anti-Sm positivity among a large cohort of MRL/lpr mice ofknown lineage showed no evidence for genetic, parental, or environmental factors that might determine whether an individual became anti-Sm positive. These data suggested that the initiation of the anti-Sm response depends on stochastic factors in the ontogeny of an individual, and that once an animal becomes positive, its response is amplified by a positive feedback system. Such stochastic factors must interact with genes in the MRL background, as only this strain spontaneously produces anti-Sm antibodies.
In the current study, we have developed a model of a feedback system by determining the effect of passively infused anti-Sm antibodies in SLE mice. Our findings confirm that some anti-Sm monoclonal antibodies can favor the further endogenous production of this specificity (7, 8) . We have determined that this effect requires the appropriate genetic background, that it is antigen-specific, that it probably does not operate through idiotypic networks or through a single isotype, and that it probably requires recognition of particular epitopes on the D peptide of the Sm complex. In addition, serial analysis ofthe fine specificity of sera from MRL mice that spontaneously developed anti-Sm antibodies was consistent with a special role of the D peptide in initiating the anti-Sm response.
Methods
Mice. MRL/Mp-lpr/lpr (MRL/lpr), MRL/Mp-+/+ (MRL/+), and C57BL/6-lpr/lpr (B6-lpr) were obtained from our colony at the University of North Carolina at Chapel Hill or directly from the Jackson Laboratory (Bar Harbor, ME Assays. Anti-Sm antibodies were detected by immunodiffusion against rabbit thymus extract, as described (2) . In some experiments, sera were also tested by ELISA, using affinity-purified rabbit Sm (14) . The IgG subclass of anti-Sm antibodies was similarly determined by ELISA, as previously reported (5) . Anti-chromatin antibodies were also measured by ELISA, using chicken erythrocyte chromatin (15 The detection of spontaneous anti-Sm antibody production in the presence of the passively administered antibody did not pose a problem for several reasons. 2G7 antibody, by itself, is not precipitating, and thus was not detected in the doubleimmunodiffusion screening. In addition, the amount of passive antibody that remained 1 wk after injection was, in most cases, substantially less than the amount detected by ELISA in those mice that had begun endogenous production. Passive antibody administration was discontinued in those animals that had become immunodiffusion-positive, so that subsequent bleeds would have vanishingly small amounts of persisting passive antibody. Furthermore, as demonstrated below, the isotype and the idiotype of the endogenously produced anti-Sm antibody could not be explained by the passively administered material.
Passively administered anti-Sm antibody increased the likelihood of endogenous anti-Sm production preferentially in mice with the genetic capacity to produce this autoantibody spontaneously (6) . As shown in Fig. 1 , MRL/lpr treated with 2G7 developed the early appearance of anti-Sm antibodies (30% of mice positive at 12 wk of age), and by 5 mo of age (16 wk after injection) > 80% were positive. MRL/lpr mice injected with the 5N control antibody developed the expected 25-30% prevalence of anti-Sm positivity at 5 mo of age. In contrast, B6/lpr mice, which do not spontaneously produce anti-Sm antibodies, were much less affected by the 2G7 injections, as only a single animal became positive at 6 mo of age. MB/lpr mice, which normally have about a 4% incidence of anti-Sm antibodies at 5 mo of age (unpublished data), tended to be intermediate in their susceptibility to anti-Sm induction by 2G7. Only one BM/lpr mouse has responded, although fewer such mice have been investigated.
Effects of different monoclonal anti-Sm antibodies. Four different anti-Sm monoclonal antibodies were used in the passive-antibody experiments: 2G7 and Y2 (both IgG2a, K), and 7.13 and Y 12 (both IgG3, K). Isotype-matched control proteins of other specificities were also administered. As shown in Fig. 2 , which illustrates pooled data from three experiments with similar results, 2G7 was the most potent in inducing anti-Sm antibodies, but 7.13 also had a significant effect. The control antibodies SN and 220 induced no more anti-Sm than would be expected to occur spontaneously, while the Y2 and Y12 antibodies suppressed endogenous anti-Sm production. The weekly administration of Y2 to- Fig. 2 were confirmed by ELISA (not shown). Interestingly, the amounts of anti-Sm antibody in immunodiffusion-positive sera did not depend on the mode of induction (Table II) , except for somewhat lower values in 7.13-treated animals (P < 0.05).
The differing effects of the various monoclonals tested suggested a possible role for isotype or idiotype in the induction of anti-Sm. However, the fact that monoclonals of two isotypes (IgG2a, IgG3) could either induce anti-Sm (2G7, 7.13) or suppress anti-Sm (Y2, Y12) argued against a simple isotype-related mechanism. In addition, the relative IgG subclass distribution of anti-Sm antibodies in mice receiving 2G7 or 7.13, and in controls was remarkably consistent (Fig. 3) . This would not be expected if, for example, the mechanism of 2G7 anti-Sm induction involved isotype-specific T cell help or suppression ( 17) . The amounts of anti-Sm activity, with essentially no 2G7 idiotype activity. Mice that had initiated their own endogenous production of anti-Sm and had gone for at least a month without passive anti-Sm had much higher levels of anti-Sm than was seen early in the course of the experiment. However, the amount of 2G7 idiotype-bearing anti-Sm antibodies of these mice was still very low, even in the group that had been treated with 2G7 (1 jtg/ml on the average).
Specificity ofanti-Sm passive enhancement. The enhanced endogenous anti-Sm antibody production resulted from the injection of certain anti-Sm antibodies, but not from the injection of antibodies of other specificities (see Fig. 2 ). Con- versely, the enhancement ofanti-Sm autoantibody expression induced by these anti-Sm antibodies did not affect the titers of anti-chromatin antibodies (data not shown). In addition, the 5N monoclonal antibody, which recognizes chromatin, did not enhance endogenous anti-chromatin production over that seen in PBS-treated mice. The course of autoimmune disease, as determined by survival, was modestly accelerated in 2G7-treated mice (Fig. 4) .
Specificity of anti-Sm antibodies. The specificity of antiSm antibodies was determined by Western blotting. Fig. 5 shows the blots obtained with the monoclonal antibodies utilized. As has been reported, the 2G7 and 7.13 antibodies recognized the D peptide, while the Y2 and Y12 antibodies saw both the B and D peptides (10, 18, 19) . One serum did not show any positivity by blot. Fig. 7 shows anti-Sm Western blots of serial sera from one of these MRL/ lpr mice which spontaneously acquired anti-Sm.
Discussion
We have demonstrated that the passive administration of certain monoclonal anti-Sm antibodies induced endogenous production of anti-Sm in genetically susceptible mice. This induction was specific for anti-Sm, as anti-Sm-injected animals had no enhancement of production of anti-chromatin. Mice injected with anti-chromatin monoclonal antibody or with other monoclonals did not have enhanced anti-Sm production. The anti-chromatin monoclonal antibody utilized, 5N, which recognizes the DNA moiety of chromatin, did not enhance anti-chromatin production. However, we cannot conclude that the chromatin autoantibody system is not susceptible to the same kind of regulation until a much larger number of antibodies is tested, particularly because half ofthe anti-Sm antibodies used did not induce endogenous anti-Sm production. A similar observation of passive antibody induction of autoantibody was reported in humans for the Rh determinants (20) . The possibility of such passive antibody regulation in other autoantibody responses remains to be investigated.
The current work suggests some aspects of the mechanism ofthis antibody enhancement in the anti-Sm antibody system. First, idiotypic networks do not appear to be involved. (21, 22) . In the current work, however, the anti-Sm monoclonal antibodies that were capable of positive enhancement were of the IgG2a and IgG3 isotypes, whereas two anti-Sm monoclonals of the same isotypes appeared to be suppressive. Thirdly, the peptide specificities of the induced antibodies, as determined by Western blotting (Fig. 6) I an antigenic particle could enhance an immune response, whereas antibodies that recognized a larger set ofdeterminants were suppressive. In addition, the two enhancing anti-Sm monoclonals published by Maini and coworkers were D specific (7, 8) .
The special role of D-peptide recognition suggested by the monoclonal antibody-enhancement experiments parallels results in sequential analyses by Western blotting of sera from MRL mice that spontaneously developed anti-Sm antibodies. In every case, the initial positive serum recognized the D peptide, and in all of these sera except one only the D peptide was seen. Similar results have also been reported in a single SLE patient who by chance had serial bleeds through the time she became anti-Sm positive (24) . Although the immunoblot technique only detects a subset of the antibodies reacting with a particular antigen, these results suggest that the spontaneous anti-Sm response begins with recognition of the D peptide. The initial anti-D response could then engender an antibodymediated enhancement mechanism such as we have demonstrated.
These current results, along with our previous findings, allow us to formulate a more detailed hypothesis regarding the mechanism of anti-Sm production in SLE mice. We have previously shown that spontaneous anti-Sm occurs only in certain SLE mouse strains. Efficient induction of this specificity by passive antibody requires these same strains. This suggests that the genetic background determines certain common aspects of immunoregulation of the spontaneous and passiveantibody-induced anti-Sm responses. Even in mice with this genotype (MRL), the frequency of precursor B cells for antiSm production is very low (25) . However, as our Sm-antigen immunization experiments have shown, these B cells must arise periodically, and under the appropriate conditions will go on to make an anti-Sm response (26, 27) . We hypothesize that a spontaneous anti-Sm response requires the initial stimulation of B cells specific only for the D peptide. If anti-Sm antibodies of this unique specificity are thus expressed, a positive feedback loop is initiated, and the anti-Sm response is amplified until it becomes serologically detectable. If, on the other hand, the initial antibodies produced in response to the Sm particle bind both the B and the D peptides, then a negative feedback loop intervenes and prevents amplification ofthe response. As the combined effect of equivalent amounts of the enhancing antibody and the suppressing antibody appears to be suppressive, any response which initially included an antiSm antibody of the Y2 type (anti-B, D) would fail to be amplified.
This schema fits with the role we postulate for stochastic events in lymphocyte ontogeny that determine the anti-Sm seropositivity of an MRL SLE mouse (6) . According to this admittedly oversimplified speculation, the chance of an individual MRL/lpr animal developing an initial D peptide-specific response before the age of 5 months is -25%. That animal would become anti-Sm seropositive. On the other hand, the probability is 75% that an individual animal will initially express B/D-specific clones, such that the response would be turned off. These specificities could be determined by the random selection and somatic mutation of immunoglobulin variable region genes. The level of influence of the MRL genetic factors presumably mainly occurs after this selection of the B-cell anti-Sm specificity and functions through as yet not understood immunoregulatory mechanisms.
Our current findings are paralleled by work from Maini and co-workers (7, 8) . They have published similar results with enhancement of the anti-Sm response in MRL/lpr mice. However, they also claimed that the anti-Sm-treated animals lived longer than controls; we do not confirm this finding with a larger number of animals, and in fact we find a modestly decreased survival in anti-Sm-treated mice. These apparently conflicting results may well be due to the different monoclonal antibodies used in the two studies.
